ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C22H22ClKN6O
CAS番号:
分子量:
461.00
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
5845770
InChI key
OXCMYAYHXIHQOA-UHFFFAOYSA-N
SMILES string
CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]
InChI
1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
grade
pharmaceutical primary standard
API family
losartan
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... AGTR1(185)
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
Losartan potassium is a new drug used for hypertension. It is nonpeptide angiotensin II (AII) receptor antagonist.
Losartan potassium is nonpeptide angiotensin II (AII) receptor antagonist and is orally active. It belongs to a new class of drugs introduced for clinical trials to treat hypertension.
Application
Losartan potassium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Losartan Potassium and Hydrochlorothiazide Tablets
- Losartan Potassium Tablets
Biochem/physiol Actions
ロサルタンカリウムは、経口投与可能な強力かつ選択的な、競合的アンジオテンシンII受容体1型（AT1）アンタゴニストです。ロサルタンカリウムは高血圧の治療に使用されます。
経口投与可能な強力かつ選択的な、競合的アンジオテンシンII受容体1型（AT1）アンタゴニストです。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1370462-150MG: + 1370462-250MG:
jan
Quantification of losartan and its metabolite in rat urine
Prolina, OG, et al.
Bulletin of Moscow University, 53.3, 194-197 (2012)
D M Dorfman et al.
The Journal of biological chemistry, 267(2), 1279-1285 (1992-01-15)
Previously, we showed that the promoter of the gene encoding preproendothelin-1 (PPET-1) contains a GATA motif that is essential for activity and interacts with a nuclear factor similar in size and binding specificity to the erythroid transcription factor GATA-1. To
L M Burrell
Drug safety, 16(1), 56-65 (1997-01-01)
Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which
Tetsuhiro Kakimoto et al.
The Journal of endocrinology, 222(1), 43-51 (2014-05-02)
Diabetic nephropathy is a major complication in diabetes and a leading cause of end-stage renal failure. Glomerular podocytes are functionally and structurally injured early in diabetic nephropathy. A non-obese type 2 diabetes model, the spontaneously diabetic Torii (SDT) rat, is
K L Goa et al.
Drugs, 51(5), 820-845 (1996-05-01)
Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）